Eligibility criteria Wegovy coverage for weight loss requires prior authorization and may be approved when you meet the following criteria: For adults (18 years and older): Continuation of therapy: The patient is 18 years of age or older, and
A weekly injection
You may be a good candidate if: You are an adult with a BMI of 30 or higher, or You have a BMI of 27 or higher with at least one weight-related health condition, such as high blood pressure, high cholesterol, or heart disease
Indications and Usage Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Ozempic (semaglutide) tablets 4 mg or 9 mg are indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes Ozempic injection is indicated: to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Ozempic tablets are indicated: to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes who are at high risk for these events Important Safety Information for Ozempic WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration- dependent thyroid C-cell tumors at clinically relevant exposures
Always talk to your healthcare professional right away about any side effect that bothers you or doesn't go away
If you are losing weight steadily at 1.0 mg semaglutide, there is no urgency to escalate to 1.7 mg
